Study of DZD8586 for adults with chronic ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with persistent or chronic primary ITP (immune thrombocytopenia).
- Your average platelet count is below 30,000 (based on at least two recent blood tests).
- You have tried at least one standard ITP treatment (such as steroids or IVIG) and it didn't work.
- You are not pregnant or breastfeeding, and you are willing to follow birth control rules if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different dosing schedules of a high-dose corticosteroid called dexamethasone to see which one works better for people who have just been diagnosed with ITP (when your immune system attacks your platelets, causing low counts and bleeding). The goal is to find a treatment that raises your platelet count more effectively and safely.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
This study tests different doses of a drug called zanubrutinib (a BTK inhibitor) to find the best dose for adults with newly diagnosed ITP that hasn't been treated yet. It aims to see if this drug can safely boost platelet counts and reduce bleeding symptoms.
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This trial tests an experimental oral medication called TQB3473 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets causing low counts and bleeding risk. The goal is to see if the drug can safely improve platelet counts and reduce bleeding symptoms.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.